An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Expanded access is currently available for this treatment.
Verified March 2013 by Eisai Inc.
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT01240421
First received: October 1, 2010
Last updated: March 3, 2013
Last verified: March 2013

October 1, 2010
March 3, 2013
August 2010
March 2012   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01240421 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

This expanded access program is an open-label, multi-center study, which will consist of a PreTreatment Phase and a Treatment Phase. Patients with locally advanced or metastatic breast cancer who fulfill the eligibility criteria will be treated. The program will continue in each country until eribulin is approved, reimbursed and launched in that country, or termination of the program by the Sponsor.

Not Provided
Expanded Access
Not Provided
Not Provided
Metastatic Breast Cancer
Drug: Eribulin Mesylate
At a dose of 1.4 mg/m^2 as a 2 to 5 minute intravenous bolus on Days 1 and 8 of a 21-day cycle.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Available
Not Provided
Not Provided
March 2012   (final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • Patient's oncologist must have documented experience in a prior eribulin clinical trial.
  • Recurrent, locally advanced or metastatic breast cancer that has progressed on or after the last anti-cancer therapy
  • Prior treatment with, ineligibility for, or commercial unavailability of each of the following therapies:

    1. Anthracyclines, taxanes, and capecitabine
    2. Ixabepilone, in countries where this agent is marketed
    3. Trastuzumab, for Her-2 positive disease
    4. Hormonal therapy, in hormone receptor-positive disease
    5. All other commercially available therapies, e.g. gemcitabine or vinorelbine, used for the treatment of advanced breast cancer (see NCCN guidelines)
  • ECOG performance status greater than or equal to 2
  • Adequate kidney function: serum creatinine less than or equal to 2.0 mg/dL or creatinine clearance greater than or equal to 40 mL/min
  • Adequate bone marrow function: absolute neutrophil count greater than or equal to 1.5 x 109/L, hemoglobin greater than or equal to 10 g/dL (can be corrected by growth factor or transfusion), and platelet count greater than or equal to 100 x 109/L
  • Adequate liver function: total bilirubin less than or equal to 1.5 x upper limit of normal (ULN), alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase less than or equal to 3 x ULN (or less than or equal to 5 x ULN in case of liver metastases). If alkaline phosphatase is greater than 3 x ULN (in absence of liver metastases) or greater than 5 x ULN (in presence of liver metastases) AND patient also is known to have bone metastases, the liver specific alkaline phosphatase must be used to assess liver function instead of total alkaline phosphatase
  • Willing and able to comply with all aspects of the treatment protocol
  • Provision of written informed consent
  • Female, aged at least 18 years
  • Patients of childbearing potential must agree to be abstinent or to use a highly effective method of contraception

Key Exclusion Criteria:

Eligibility for any other eribulin study open in the same region

  • Existing anti-cancer therapy-related toxicities of grade 2 or more, except that alopecia and grade 2 neuropathy are acceptable
  • History of congestive heart failure with New York Heart Association Classification greater than grade II, unstable angina, myocardial infarction within the past 6 months or serious cardiac arrhythmia
  • Electrocardiogram with QTc interval of greater than or equal to 500 msec based upon Bazett's formula (QTcB)
  • The Investigator believes the patient to be medically unfit to receive eribulin or unsuitable for any other reason
  • Pregnancy (positive β-hCG test) or breastfeeding
  • Hypersensitivity to eribulin or any of the excipients
  • Brain or subdural metastases, unless local therapy has been completed and use of corticosteroids for this indication has been discontinued for at least 4 weeks before starting treatment in this protocol. Any signs (eg, radiologic) and/or symptoms of brain metastases must be stable for at least 4 weeks before starting the treatment protocol
  • History of or concomitant medical condition that, in the opinion of the Investigator, would compromise the patient's ability to safely complete the treatment protocol
  • Known human immunodeficiency virus positivity, as neutropenia caused by eribulin treatment may make such patients particularly susceptible to infection.
  • Meningeal carcinomatosis
  • Pulmonary lymphangitic involvement resulting in pulmonary dysfunction requiring active treatment, including use of oxygen
  • Receipt of any of the following treatments within the specified period before the start of treatment: 1) Any investigational drug within 4 weeks; 2) Chemotherapy, radiation, biological or targeted therapy within 2 weeks; 3) Hormonal therapy within 1 week.
Female
18 Years and older
No
Contact: ESI Medical Affairs ESI Medical Affairs 1-888-422-4743 eumedinfo@eisai.net
Contact: EEL EU Medical Info EEL EU Medical Info 44 207 600 1 eumedinfo@eisai.net
Belgium,   Canada,   France
 
NCT01240421
E7389-G000-398
Not Provided
Eisai Inc.
Eisai Inc.
Not Provided
Not Provided
Eisai Inc.
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP